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Abstract 16 
Penicillins are widely used to treat infections in children, however the evidence is continuing to 17 
evolve in defining optimal dosing. Modern paediatric pharmacokinetic study protocols frequently 18 
favour opportunistic, “scavenged” sampling.  This study aimed to develop a small volume single 19 
assay for five major penicillins and to assess the influence of sample degradation on inferences 20 
made using pharmacokinetic modelling, to investigate the suitability of scavenged sampling 21 
strategies.  22 
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Using a rapid ultra-high performance liquid chromatographic-tandem mass spectrometric method, 23 
an assay for five penicillins (amoxicillin, ampicillin, benzylpenicillin, piperacillin and 24 
flucloxacillin) in blood plasma was developed and validated. Penicillin stabilities were evaluated 25 
under different conditions. All penicillins were present in the same sample over the time of the 26 
storage. Using these data, the impact of drug degradation on inferences made during 27 
pharmacokinetic modelling was evaluated.   28 
All evaluated penicillins indicated good stability at room temperature (23 ± 2˚C) over 1 hour 29 
remaining in the range of 98-103% of the original concentration. More rapid analyte degradation 30 
had already occurred after 4 hours with stability ranging from 68% to 99%. Stability over longer 31 
periods declined: degradation of up to 60% was observed with delayed sample processing of up to 32 
24 hours. Modelling showed that analyte degradation can lead to a 30% and 28% bias in clearance 33 
and volume of distribution, respectively, and falsely show nonlinearity in clearance.  34 
Five common penicillins can now be measured in a single low volume blood sample. Beta-lactam 35 
chemical instability in plasma can cause misleading pharmacokinetic modelling results, which 36 
could impact upon model-based dosing recommendations and the forthcoming era of beta-lactam 37 
therapeutic drug monitoring.  38 
 39 
Introduction 40 
Penicillins have been widely used in both children(1) and adults for over 50 years and arguably 41 
remain the most important group of antibiotics. There is still considerable variation in the rate of 42 
antimicrobial prescribing in different countries(2) and also the doses used.(3) Even for very 43 
common antibiotics, such as the penicillins, there remains a marked lack of information about 44 
optimal dosing.(4) Pharmacokinetic (PK) variability in children can arise from the physiological 45 
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changes related to growth and organ maturation, and also due to pathophysiology, especially in 46 
critical illness. Selecting the best antimicrobial dose to use in children is challenging because of 47 
this extensive variability in patients’ pharmacokinetics.(5) As a result, a drug’s PK profile can be 48 
unpredictable,(6) which in the case of antibiotics can lead to subtherapeutic concentrations(7) – 49 
with associated treatment failure, and the possible emergence of antimicrobial resistance 50 
(AMR).(8) Identifying the optimum dosing regimens is thus key to improving therapeutic 51 
outcomes, reducing toxicity(9) and in limiting the development of AMR. Given the wide use of 52 
beta-lactam antibiotics in clinical practice, the knowledge of PK variability has led researchers to 53 
question whether there is a potential role for beta-lactam therapeutic drug monitoring (TDM) to 54 
help individualise dosing strategies in an intensive care unit (ICU) setting.(6)  55 
Penicillins are unstable β-lactam antimicrobials and spontaneous degradation of these drugs 56 
occurs. Diverse degradation pathways caused by the β-lactam group are common to all penicillins, 57 
yet they vary with storage conditions resulting in different degradation products.(10) One of the 58 
main challenges when determining the pharmacokinetics of these drugs is how to maintain their 59 
stability in biological samples under various storage conditions. The instability of penicillins, 60 
which is already well established, can result from the β-lactam ring opening in acidic and basic 61 
conditions, enzymatic (hydrolysis and aminolysis) degradation and degradation by the presence of 62 
metal ions and from temperature changes(10). Therefore, detailed stability (ST%) studies during 63 
bioanalytical assay validation are crucial. The most important stability from the clinical study 64 
perspective is the short term stability, taking into account possible delays and interferences during 65 
the sampling and sample handling in the hospital (both at the bedside and also when transporting 66 
the sample from the patient to the laboratory). 67 
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Importantly, opportunistic or so-called “scavenged” sampling techniques are being used 68 
increasingly in paediatric PK studies as a sparse sampling methodology.(11, 12) These approaches 69 
mean that the blood samples from patients are initially processed in the same way as routine blood 70 
samples required for clinical care, before being processed and stored specifically for antibiotic 71 
quantification, the results of which are then used for pharmacokinetic analysis. The use of 72 
scavenged sampling itself, which incorporates processing delays into the standard operating 73 
procedures, thus might influence the PK analysis results in the case of chemically unstable drugs. 74 
Understanding the impact of such delays on both laboratory and pharmacometric analysis is 75 
particularly important as opportunistic, scavenged sampling methods are now being further 76 
advocated specifically for neonatal pharmacokinetic studies (13).  77 
Numerous simultaneous bioanalytical methods have been developed over the years for beta-lactam 78 
antibiotics (14-22), with evidence of increased interest recently (16, 18, 20). The number of 79 
simultaneously determined drugs varies (maximum 21 (17)) and the required sample volumes 80 
range from as little as 20 µL(21) and 50 µL (14, 16, 18, 19, 22) up to 1 mL(17).  81 
The aim of this laboratory study was to develop and validate a bioanalytical method for measuring 82 
penicillins in small-volume plasma samples from paediatric and neonatal patients, in order to use 83 
the data for population PK modelling and dose optimisation studies.(2, 23) The influence of sample 84 
degradation on measured concentrations was then studied using pharmacokinetic modelling in 85 
order to evaluate the suitability of scavenged sampling strategies for the penicillins as chemically 86 
unstable drugs. The penicillins studied included amoxicillin, ampicillin, benzylpenicillin 87 
(penicillin G), piperacillin and flucloxacillin (Figure 1). The bioanalytical methods were developed 88 
for the Neonatal and Paediatric Pharmacokinetics of Antimicrobials study (NAPPA: EudraCT 89 
2013-002366-40, NCT01975493).(24) 90 
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 92 
***Figure 1 goes here*** 93 
  94 
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Results  95 
LC-MS method development  96 
The LC-MS assay was developed to simultaneously quantify concentrations of 5 major penicillins 97 
in blood plasma. Chromatographic separation was achieved within 4 minutes for all analytes 98 
(representative chromatogram from the sample with concentration 25 mg/L, Figure 2): amoxicillin, 99 
ampicillin, benzylpenicillin, piperacillin and flucloxacillin.  100 
***Figure 2 goes here*** 101 
 102 
Method validation and selectivity 103 
The method was fully validated according the European Medicines Agency (2011) Guideline on 104 
bioanalytical method validation(25). Selectivity was evaluated analysing blood plasma samples 105 
from six different sources.  106 
Lower limit of quantification (LLOQ) 107 
For all analytes the LLOQ was 0.1 mg/L. The within-day accuracy for amoxicillin ranged from 108 
98-106%, for ampicillin from 105-110%, for penicillin G from 105-108%, for piperacillin from 109 
97-106% and for flucloxacillin from 96-105% at the LLOQ level. Within-day precision for 110 
amoxicillin ranged from 2.5-5.4%, for ampicillin from 2-3.5%, for penicillin G from 4.6-10.6%, 111 
for piperacillin from 2.9-4.2% and for flucloxacillin from 4.3-11.7% at the LLOQ level. 112 
Signal to noise ratio remained higher than 5 for all analytes, ranging from 89 to 251. 113 
Calibration, carry-over, matrix effects, accuracy and precision 114 
Nine calibration concentration levels (0.1, 0.5, 1, 5, 25, 60, 100, 150 and 200 mg/L) were used to 115 
compose the matrix matched calibration lines, in addition to the calibrators the blank sample 116 
(processed using internal standard) and the double blank sample (processed without internal 117 
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standard) were analyzed. All samples were analysed in duplicates. Back calculated concentrations 118 
using linear regression fitting with 1/x2 weighting (Table 1) ranged from 96-110% for all analytes 119 
in all concentration levels from 0.1 mg/L to 200 mg/L. 120 
***Table 1 goes here*** 121 
Carry-over (presented in supplementary data file) was considered acceptable for all analytes and 122 
the IS. Matrix effects (presented in supplementary data file) and the calibration (sTable 1) were 123 
evaluated for all analytes. Matrix effects ranged from 96 to 107.6 % for all penicillins.  124 
Accuracy and precision was tested in four different concentrations (in 5 replicates): 0.1 mg/L (as 125 
LLOQ), 0.5 mg/L as low concentration, 50 mg/L as medium concentration and 150 mg/L as high 126 
concentration.  127 
Within-run and between-run assay accuracies for all analytes ranged from 1.4% to 10.5% at LLOQ 128 
concentration and from 0.3% to 8.8% for the low, medium and high concentrations, respectively 129 
(Table 2 and 3). Within-run assay precisions for all analytes ranged from 2.0 to 6.1% at LLOQ 130 
concentration and from 2.0% to 5.4% for low, medium and high concentrations (Table 2). 131 
Between-run assay precision for all analytes ranged from 1.6 to7.3% at LLOQ concentration and 132 
from 1.3% to 7.4% for low, medium and high concentrations (Table 3). 133 
***Table 2 goes here*** 134 
***Table 3 goes here*** 135 
 136 
 137 
Stability 138 
Short term stability of analytes in blood plasma at room temperature.  139 
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Short term stability data of the penicillin-containing plasma samples when stored at room 140 
temperature (23 ± 2˚C) for 24 h indicated degradation of flucloxacillin, piperacillin and penicillin 141 
G in the plasma samples (at low, medium and high concentrations), since only 40-63%, 52-64% 142 
and 66-70%, respectively, of the drug was detectable after applying room temperature as a stress 143 
condition. Ampicillin and amoxicillin however had slightly better stability on the bench-top, with 144 
89-96% and 71-89%, respectively, of the drugs detectable after 24 h at room temperature.  145 
In addition, short term stability was tested over a 4 h period at room temperature, which also 146 
indicated compound degradation: flucloxacillin, piperacillin and penicillin G maintained 68-80%, 147 
83-89% and 89-95% of their original concentration. Ampicillin and amoxicillin both remained in 148 
the range of 95-98% and 96-99% after 4 h at the room temperature. 149 
All penicillins indicated good stability at room temperature over 1 h remaining in the range of 98-150 
103% from the original concentration.  151 
Autosampler stability  152 
Rapid degradation of ampicillin occurred in the samples kept in the cooled (+10 ˚C) 153 
autosampler for 24 h: only 35-57% of the original drug concentration remained in the samples. 154 
However, all other penicillins maintained 85-99% of their original content. In order to improve the 155 
autosampler stability, rapid analysis of beta-lactams is required. Therefore, ampicillin stability was 156 
tested over shorter time-periods. Within a 10-hour period, approximately 92-96% of ampicillin 157 
original concentration remained in the samples stored in the autosampler in five replicates. 158 
 159 
***Figure 3 goes here*** 160 
Freeze and thaw stability  161 
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The freeze-thaw stability of ampicillin also indicated the degradation of the compound in plasma 162 
samples, since 82-99% of the original content remained to the plasma samples after 3 freeze-thaw 163 
cycles, while the other penicillins maintained approximately 98-100% of their original content in 164 
the plasma samples.  165 
Long term stability  166 
Long term stability of analytes in the plasma samples was evaluated over 6 month time-period at-167 
80˚C. All penicillins remained within the range of 95-104% of their original content at low, 168 
medium and high concentrations (tested in five aliquots of the same sample, i.e. n=5).  169 
  170 
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PK modelling and simulations results  171 
Table 4 gives the estimated piperacillin CL at different dose levels assuming varying levels of 172 
degradation using the doses reported by Landersdorfer et al(26) (3000 mg and 1500 mg), the 173 
current usual dose (4000 mg) and 400 mg for illustration of a 10-fold range. 174 
***Table 4 goes here*** 175 
 176 
Discussion 177 
A simultaneous method for measuring amoxicillin, ampicillin, benzylpenicillin, piperacillin and 178 
flucloxacillin was developed. To the best of our knowledge, the combination of these five 179 
penicillins using sample volumes as low as 50 µL in a single LC-MS assay has not previously been 180 
reported, although other simultaneous beta-lactam LC-MS assays have been described(15, 17, 21, 181 
22). As the associated clinical study (NAPPA) was investigating penicillin pharmacokinetics in 182 
neonatal and paediatric patients, the main challenge of the method development was the restricted 183 
sample volume in this patient population. Knowing the stability issues of beta-lactam antibiotics, 184 
sample preparation was done rapidly using protein precipitation and dilution afterwards to avoid 185 
unnecessary contamination of the LC-MS system from the high content of sample matrix.  186 
Using data from the stability studies during method development, the impact of analyte 187 
degradation was assessed, and we have shown, using piperacillin as an example drug, that 188 
inferences made during PK modelling may be biased if analytes have degraded within clinical 189 
samples. As scavenged sampling methods are increasingly recommended for neonatal 190 
pharmacokinetic studies, these findings are of clear significance and serve as an important 191 
reminder of tailoring scavenged sampling protocols in future paediatric pharmacokinetic studies 192 
according to each specific analyte’s stability. Furthermore, given the growing interest in the use of 193 
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TDM for beta lactams(6) to optimize pharmacotherapy in clinical practice these findings have 194 
further implications for TDM sampling protocols. 195 
Rapid and simultaneous multi-drug assays are the key for successful TDM services which need to 196 
be delivered in a timely manner.(22) This novel assay, which has both good accuracy and good 197 
precision, also benefits from rapid sample preparation and decreased matrix effects compared to 198 
previous assays, (15) even when more complex and cleaner sample preparation was used. The 199 
lower matrix effects obtained were most likely due to the appropriate dilution during sample 200 
preparation.  201 
One of the key validation parameters for beta-lactams is stability, both short- and long-term. 202 
Despite previous recognition of both the instability of beta-lactams at room temperature and the 203 
importance of pre-analytical stability(27), there is a persisting lack of stability data in published 204 
assay validations.(17, 22) Our results indicated more rapid degradation in plasma samples with 205 
EDTA for piperacillin and amoxicillin than reported in the literature previously for lithium-206 
heparinized tubes and tubes without the gel separator.(27) Another study(15) indicated slightly 207 
better stability over 4 h at room temperature for penicillin G, piperacillin and flucloxacillin without 208 
mentioning the anticoagulant used for plasma. Importantly, beyond assay validation, we then 209 
sought to interrogate the chemical stability data to understand in a quantifiable way its potential 210 
impact on the output from pharmacokinetic modelling, which when used for model-based dosing 211 
recommendations could have direct clinical implications in future. 212 
From the results of the pharmacokinetic modelling, it can be seen that, in the absence of sample 213 
degradation, the estimated CL was close to the simulated value, and whilst CL did increase with 214 
increasing processing time, it was not until samples were left for 24 hours that degradation started 215 
to falsely show nonlinearity.  It should be noted however that the nonlinear CL reported by 216 
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Landersdorfer et al(26) included data on urinary piperacillin. Since we did not test piperacillin 217 
stability in urine, it is still possible that more rapid urinary piperacillin degradation coupled to 218 
longer times between sample collection inherent in urinary pharmacokinetic studies may enhance 219 
an apparent nonlinear pharmacokinetic effect. 220 
In the assessment of scavenged sampling, the estimates for CL and V were 11.3 L/h and 12.3 L, 221 
when sample degradation was assumed not to have occurred. Whilst for a more complex 2-222 
compartment pharmacokinetic model, scavenged sampling has been shown to bias parameter 223 
estimates and should therefore generally not be preferred over optimally timed samples(28), this 224 
result indicates that for this simple 1-compartment model the scavenged design could potentially 225 
work if samples were processed immediately. It should be noted that truly immediate processing 226 
is rarely possible in a clinical environment, however, when it comes to so-called ‘scavenged’ 227 
samples. Further, when degradation was allowed by having samples processed between 4 and 24 228 
hour post collection (representing lengths of delays that can occur when samples are scavenged 229 
from the laboratory), the CL and V were 14.3 L/h and 15.4 L respectively. This represents a 30% 230 
and 28% bias in CL and V which could potentially cause unnecessarily high doses to be 231 
recommended on the basis of pharmacometric (PK model-based) analyses.  Indeed, the authors of 232 
the scavenged sampling study(11) acknowledge this potential problem, and further penicillin 233 
studies using scavenged samples require accurate recording of sample processing times so that 234 
degradation can be accounted for during pharmacokinetic modelling. Nonetheless, for future beta-235 
lactam TDM methods, we have demonstrated the acceptability of storage for up to one hour at 236 
room temperature for plasma samples collected from patients, which is very promising, and this 237 
should make the TDM standard operating procedures both realistic and acceptable in the context 238 
of a busy clinical setting.  239 
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To our knowledge this is the first study to use data obtained during bioanalytical method validation 240 
to demonstrate how the use of scavenged sampling methods could impact significantly upon the 241 
results of pharmacokinetic modelling. This is relevant when dealing with unstable analytes present 242 
in patient samples destined for drug quantification assays, whether these be samples for paediatric 243 
pharmacokinetic research using opportunistic sampling strategies, or samples from ICU patients 244 
intended for TDM. These findings underscore the importance of detailed evaluation of the stability 245 
of beta-lactam antibiotics in specific matrices during the bioanalytical method validation. This is 246 
not only important for planning the laboratory workflow, but also should be considered all the way 247 
from bedside to bench, with consideration of sample collection methods, transportation and 248 
storage. For researchers developing dosing guidance using pharmacokinetic analyses of such data, 249 
the instability of these analytes can cause significant bias in the prediction of pharmacokinetic 250 
parameters. With the implementation of novel TDM initiatives based on individualized 251 
pharmacokinetic profiles and forecasting, this could lead to suboptimal dosing recommendations, 252 
which could adversely affect clinical outcomes. However, when carefully evaluated, the instability 253 
can be accounted for when creating pharmacokinetic models. This work highlights the importance 254 
of continued close collaboration between bioanalytical chemists, pharmacometricians, and 255 
clinicians when developing novel TDM protocols. For future work we would recommend that the 256 
importance of strict sampling handling procedures be incorporated into all standard operating 257 
procedures for beta-lactam TDM methods, to ensure that our knowledge of beta-lactam stability is 258 
fully embedded in forthcoming innovative dose individualization strategies. A potentially simple 259 
way to overcome these challenges is through the use of point-of-care methods for beta-lactam 260 
quantification at the bedside, which if economically viable, would present an ideal solution.  261 
 262 
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Materials and methods  263 
Instrumentation 264 
Chromatographic separation and mass spectrometric detection of five analytes were carried out 265 
using Waters Acquity UPLC (Ultra High Performance Liquid Chromatography) system equipped 266 
with Waters TQ Detector (Waters, Milford, USA). The UPLC system consists of a binary solvent 267 
manager, a sample manager and a column thermostat. ESI-MS detection was carried out in positive 268 
ion detection mode. The UPLC-MS/MS instrument was controlled by Waters MassLynx software 269 
version 4.1 (Waters, Milford, USA). Data analysis was carried out using TargetLynx software 270 
version 4.1 (Waters, Milford, USA).  271 
 272 
Chemicals 273 
Pharmaceuticals – ampicillin, amoxicillin, flucloxacillin, penicillin G, piperacillin and an internal 274 
standard (IS), penicillin G-D7 N-ethylpiperidinium salt and LC-MS grade methanol and formic 275 
acid were purchased from Sigma (St. Louis, MO, USA). Acetonitrile was obtained from Rathburn 276 
Chemicals Ltd (Walkerburn, Scotland). Water was purified (18.2 MΩ*cm at 25 °C and a TOC 277 
(total organic carbon) value below 3 ppb) in house using a Millipore Advantage A10 system from 278 
Millipore (Bedford, USA). Blood plasma with EDTA was obtained from the Biological Specialties 279 
Corporation (Colmar, PA, USA).  280 
 281 
Sample preparation  282 
Plasma samples were kept at –80°C for storage. For analysis they were removed from the freezer 283 
and kept at room temperature for thawing. Once at room temperature, matrix matched calibrators 284 
and quality control samples were mixed on an IKA Vibrax VXR mixer (Esslab, Essex, England). 285 
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For 50 µL of each calibrator and quality control sample, 200 µL of internal standard (penicillin G-286 
D7) in acetonitrile (stored at -20 C, prepared once every two weeks) was added. Samples were 287 
mixed on the IKA Vibrax VXR for 5 minutes and centrifuged at 13500 x g for 5 minutes. 1000 µL 288 
of de-ionized water was added to 100 µL of supernatant and then the samples were vortexed for 289 
10 seconds. 10 µL of the sample was injected into the LC-MS/MS (liquid chromatography with 290 
tandem mass spectrometry) system. 291 
 292 
Liquid chromatography-mass spectrometry 293 
For the chromatographic separation of penicillins, 0.1% formic acid in water (mobile phase A) and 294 
0.1% formic acid in methanol (mobile phase B) with gradient elution and a reversed phase 295 
analytical column (50mm x 2.1mm; 1.7 µm Acquity UPLC BEH C18) was used. Separation was 296 
obtained using the gradient program starting from 5% of mobile phase B for the first 1.2 minutes 297 
(directed to the waste), mobile phase B content was raised to 100% over 2.3 minutes and kept at 298 
100% for 1 minute, thereafter lowered again to 5% over 0.2 minutes and kept at 5% of mobile 299 
phase B for 1.8 minutes. Eluent flow rate was 0.25 mL/min. Electrospray (ESI) interface was in 300 
use for the mass-spectrometric detection in the positive multiple reaction monitoring (MRM) mode 301 
for detection of penicillins. Triple quadrupole detector transitions m/z 335  [M+1];  -> m/z 160; 302 
176 (for penicillin G); m/z 350  [M+1] -> m/z 160; 106 (for ampicillin); m/z 366  [M+1] -> m/z 303 
114; 208 (for amoxicillin); m/z 518  [M+1] -> m/z 143; 160 (for piperacillin); m/z 454 [M+1] -> 304 
m/z 160; 295 (for flucloxacillin), and m/z 342  [M+1] -> m/z 160 (for penicillin G-D7, IS) were 305 
used for quantification and qualification.   306 
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Optimised parameters for ESI and MS were used with capillary voltage of 0.8 kV, cone voltage 307 
31 V, source temperature 120°C, desolvation gas temperature 350°C and desolvation gas flow rate 308 
800 L/h and cone gas flow rate 30 L/h. 309 
Stability experiments  310 
Short term stability data of the penicillin-containing plasma samples were obtained by storage of 311 
quality control samples (at low, medium and high concentrations) at room temperature (23 ± 2˚C) 312 
for 4 h and 24 h and comparing the results with the analysis performed at the starting time (time 0 313 
h) of the analysis. The freeze-thaw stability of penicillins was evaluated in low and high 314 
concentration plasma samples (each in 5 replicates) after 3 freeze-thaw cycles. Plasma samples 315 
were kept frozen at -80˚C and thawed, keeping them at the room temperature (23±2 C) for 1 h. 316 
Thereafter, samples were refrozen and thawed again after 24 h. Long term stability of analytes in 317 
the plasma samples was evaluated for the storage over 6 month time-period at -80˚C (each tested 318 
in 5 aliquots of the sample plasma sample, i.e. n=5). Autosampler stability at the temperature of 319 
+10 ˚C was evaluated over 24 h.  320 
Each time freshly prepared calibration solutions were measured and the concentration in quality 321 
control samples was calculated. Stability of the analyte was evaluated as following:  322 
  % =
  
  
, 323 
where c0 is the initial concentration, determined without introducing any extra pauses in the 324 
analysis process; ct is the concentration obtained when analysis is carried out with making a 325 
pause with duration t in the analysis. 326 
 327 
Pharmacokinetic modelling and simulations  328 
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To assess the impact of drug degradation on inferences made during pharmacokinetic modelling, 329 
data from the stability tests was used. The slope of the log concentration with time was estimated 330 
for each initial concentration of each drug using linear regression in the statistical software R 331 
version 3.1.0(29). Piperacillin was chosen as the model drug to assess the impact of sample 332 
degradation on two aspects of pharmacokinetic modeling results: reported nonlinearity in 333 
clearance (CL) and the utility of laboratory scavenged samples. 334 
To investigate whether more rapid sample degradation at lower concentrations could account for 335 
observed nonlinear pharmacokinetics, concentration-time data were simulated using NONMEM 336 
version 7.3.  The 1500 mg and 3000 mg doses described by Landersdorfer et al 2002(26) were 337 
used.  This study estimated a 3-compartment model using NONMEM version 7.3(30) and found 338 
nonlinear clearance  with 3000 mg yielding a value of 11.0 L/h whereas 1500 mg yielded a CL of 339 
13.5 L/h.  In this study the renal component of CL, estimated by urinary piperacillin excretion, 340 
decreased 24% with a doubling of dose. Simulated data were adjusted according to the degradation 341 
rate constants estimated above (with linear extrapolations made to account for changing rate 342 
constant with concentration) to assume samples were left for 1, 2, 4, 8 and 24 hours post collection 343 
before freezing, in keeping with known scavenged sampling protocols.  Using this adjusted data, 344 
CL was recalculated using noncompartmental pharmacokinetic estimation of AUC(0-∞) (the area 345 
under the plasma drug concentration-time curve).  Under the hypothesis of linear CL, the PK 346 
profiles for 4000, 1500, and 400 mg were also simulated and the above degradation adjustment 347 
made to the simulated concentrations in order to assess whether more rapid degradation of lower 348 
concentrations could yield apparent nonlinear CL upon re-estimation.    349 
To investigate the effect of laboratory scavenged samples (any excess from routine clinical 350 
samples assayed for piperacillin when reaching the lab), as reported by Cohen-Wolkowiez et 351 
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al(11), the above model was simplified to a one compartment structure with CL of 11 L/h and 352 
volume of distribution (V) of 12 L.  Fifty simulated subjects received 3000 mg 8 hourly over a 32-353 
hour interval (i.e. 4 dose intervals) and 4 random sample times within this interval were simulated 354 
from a uniform distribution. The simplified model was used to simulate concentration-time profiles 355 
assuming inter-individual variability on CL and V to be 30% and proportional residual variability 356 
to be 10%.  The simulated concentrations were then adjusted according to the procedure described 357 
above to assume degradation. The time of processing for each sample was randomly generated 358 
from a uniform distribution with an interval of 4-24 hours.  Pharmacokinetic parameters were then 359 
estimated from the adjusted and unadjusted datasets to assess potential bias caused by degradation.  360 
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Figure 1. Chemical structures of amoxicillin (a), penicillin G (b), piperacillin (c), flucloxacillin 490 
(d) and ampicillin (e).   491 
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Figure 2. Chromatograms in the plasma sample with concentration 25 mg/L for amoxicillin (A), 494 
ampicillin (B), piperacillin (C), penicillin G (D), flucloxacillin (E) and penicillin G-D7, IS (F).  495 
 496 
 497 
Figure 3. Average autosampler stability of penicillins over 10 and 24 h (n=5), error bars represent 498 
the ±1 standard deviation.  499 
Table 1. Calibration line parameters for all analytes. 500 
Analyte Slope Intercept Weighting Coefficient of Determination (r2) 
Amoxicillin 0.1120 0.0087 1/x2 0.9997 
Ampicillin 0.5005 0.0008 1/x2 0.9998 
Penicillin G 0.0241 0.0042 1/x2 0.9996 
Piperacillin 0.0447 0.0018 1/x2 0.9999 
Flucloxacillin 0.0192 0.0012 1/x2 0.9992 
 501 
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Table 2. Within-run assay precision and accuracy (% mean deviation from the nominal 502 
concentration) (n=5). 503 
 Accuracy (%) Precision (%) 
Analyte LLOQ 
0.1  
mg/L 
Low 
0.5  
mg/L 
Medium 
50  
mg/L 
High 
150 
mg/L 
LLOQ 
0.1 
mg/L 
Low 
0.5 
mg/L 
Medium 
50  
mg/L 
High 
150 
mg/L 
Amoxicillin -6.6 6.8 -3.3 -4.7 6.1 5.4 3.1 3.8 
Ampicillin 5.1 5.6 0.3 -3.9 3.4 2.0 2.5 3.8 
Penicillin G 4.7 8.8 1.5 6.6 2.0 5.0 3.7 3.3 
Piperacillin 1.4 -2.2 2.4 -3.5 2.7 3.0 4.4 3.5 
Flucloxacillin 2.1 5.2 1.2 -5.1 4.6 4.4 2.4 3.1 
 504 
505 
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Table 3. Between-run assay precision and accuracy (n=3). 506 
 Accuracy (%) Precision (%) 
Analyte LLOQ 
0.1  
mg/L 
Low 
0.5  
mg/L 
Medium 
50  
mg/L 
High 
150 
mg/L 
LLOQ 
0.1 
mg/L 
Low 
0.5 
mg/L 
Medium 
50  
mg/L 
High 
150 
mg/L 
Amoxicillin -10.5 -0.7 1.8 1.2 7.3 5.1 5.6 2.5 
Ampicillin 7.6 2.8 1.8 -1.4 2.3 5.3 5.6 1.3 
Penicillin G 7.5 4.8 -2.6 -3.2 1.6 5.7 5.7 2.6 
Piperacillin 1.8 5.7 1.5 -3.7 4.1 4.7 7.4 3.2 
Flucloxacillin 2.2 5.7 1.5 -1.3 4.7 5.0 7.0 2.2 
 507 
 508 
Table 4. Effect of sample degradation on potential conclusion of nonlinear piperacillin CL.  A 509 
simulated CL of 11.0 L/h was used for all doses (assumed linear pharmacokinetics). 510 
 511 
Dose CL (L/h) following varying delay in sample processing 
0 h 1 h 2 h 4 h 8 h 24 h 
4000 mg 10.9 11.1 11.2 11.6 12.3 15.5 
3000 mg 10.9 11.1 11.3 11.7 12.6 16.4 
1500 mg 10.9 11.2 11.4 11.9 12.9 18.1 
400 mg 10.9 11.2 11.5 12.1 13.5 20.4 
 512 
